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Abstract
Background: Recent development in the field of COPD has focused on strategies aimed at
reducing the underlying inflammation through selective inhibition of the phosphodiesterase type IV
(PDE4) isoform. Although the anti-inflammatory and bronchodilator activity of selective PDE4
inhibitors has been well documented, their low therapeutic ratio and dose-dependent systemic side
effects have limited their clinical utility. This study examined the effect of 2'-deoxy-2'-Fluoro-β-D-
Arabinonucleic Acid (FANA)-containing antisense oligonucleotides (AON) targeting the mRNA for
the PDE4B/4D and 7A subtypes on lung inflammatory markers, both in vitro and in vivo.
Methods: Normal human bronchial epithelial (NHBE) cells were transfected with FANA AON
against PDE4B/4D and 7A alone or in combination. mRNA levels for target PDE subtypes, as well
as secretion of pro-inflammatory chemokines were then measured following cell stimulation. Mice
were treated with combined PDE4B/4D and 7A AON via endo-tracheal delivery, or with
roflumilast via oral delivery, and exposed to cigarette smoke for one week. Target mRNA
inhibition, as well as influx of inflammatory cells and mediators were measured in lung lavages. A
two-week smoke exposure protocol was also used to test the longer term potency of PDE4B/4D
and 7A AONs.
Results: In NHBE cells, PDE4B/4D and 7A AONs dose-dependently and specifically inhibited
expression of their respective target mRNA. When used in combination, PDE4B/4D and 7A AONs
significantly abrogated the cytokine-induced secretion of IL-8 and MCP-1 to near baseline levels. In
mice treated with combined PDE4B/4D and 7A AONs and exposed to cigarette smoke, significant
protection against the smoke-induced recruitment of neutrophils and production of KC and pro-
MMP-9 was obtained, which was correlated with inhibition of target mRNA in cells from lung
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lavages. In this model, PDE AONs exerted more potent and broader anti-inflammatory effects
against smoke-induced lung inflammation than roflumilast. Moreover, the protective effect of
PDE4B/4D and 7A AON was maintained when a once-weekly treatment schedule was used.
Conclusion: These results indicate that inhaled AON against PDE4B/4D and 7A have unique
effects on biomarkers that are believed to be important in the pathophysiology of COPD, which
supports further development as a potential therapy in this disease.
Background
Chronic obstructive pulmonary disease (COPD) is a com-
plex syndrome characterized by chronic bronchitis, per-
sistent cellular inflammation and progressive
deterioration of airways and emphysema [1-3], for which
cigarette smoking is by far the most important risk factor
[4]. COPD is one of the leading causes of death and mor-
bidity worldwide [5]. To date, no therapies have been
shown to reduce mortality or prevent disease progression.
Although the composition of the lung cellular infiltrate
varies among COPD patients, it is mainly constituted by
neutrophils, macrophages and CD8+ T cells [6]. The neu-
trophilic arm of airway inflammation is believed to be at
the forefront of the lung pathogenesis in COPD patients
[1,7-9]. In the airways, neutrophils can release a number
of mediators including oxygen radicals, elastases and met-
alloproteases (MMP) that contribute to self-perpetuation
of inflammation and promote matrix breakdown, leading
to alveolar destruction and emphysema [10-12]. Patients
with COPD have an increased number of neutrophils in
broncho-alveolar lavages (BAL), sputum, airways and
lung parenchyma [8,9], which directly correlates with dis-
ease severity [13]. Their recruitment and accumulation in
the airways is driven by chemokines such as interleukin-8
(IL-8), the levels of which have been found to be increased
in sputum, alveolar macrophages and bronchial epithe-
lium obtained from COPD patients [14-16].
In airways, elevation of intracellular cAMP has been asso-
ciated with the general suppression of activity of inflam-
matory cells and relaxation of airway and vascular smooth
muscle [17]. Levels of intracellular cAMP are determined
by the enzymatic balance between synthesis by adenylate
cyclase and hydrolysis by phosphodiesterases (PDE). The
PDEs represent a large family of isozymes [18], of which
PDE4B and PDE4D isotypes are predominantly expressed
in a variety of inflammatory and structural lung cells [17],
and have been shown to modulate the inflammatory
response [19,20]. Small molecule PDE4 inhibitors with
broad spectrum anti-inflammatory effects have been
shown to reduce inflammatory cell recruitment and
improve lung function in animal models of COPD [21-
23]. Orally active PDE4 inhibitors such as cilomilast and
roflumilast have reached an advanced clinical stage [24-
26]. However one major hurdle in their development has
been overcoming the dose-limiting systemic side effects,
of which headaches, nausea and vomiting are the most
common manifestations [27]. Moreover, arteritis and vas-
culitis in the gastrointestinal tract and mesenteric blood
vessels of rodents [28] and cardiac tissue of primates [29]
have also raised a concern about their safety profile.
Although delivery of PDE4 inhibitors via inhalation could
represent an alternative approach [22,30], the efficacy and
safety of inhaled small molecules PDE4 inhibitors
remains to be demonstrated [31,32]. Consequently,
improving the therapeutic ratio of PDE4 inhibitors still
represents an important challenge.
One strategy to overcome these limitations is to develop
more selective PDE4 inhibitors. For example, as systemic
PDE4D inhibition appears to be responsible for the
emetic effect [33], PDE4B-specific inhibitors might pro-
vide better therapeutic ratios. However, as PDE4D also
has a predominant role in the activation of T cells [34],
PDE4B-specific inhibitors might display reduced efficacy
as compared to inhibitors targeting both isoforms in the
lung. Another interesting approach would be to develop
inhibitors of other PDE classes to be used in combination
with PDE4 inhibitors, with the goal of maintaining or
enhancing efficacy while reducing the dose-limiting side
effects associated with these drugs [35]. In this regard,
PDE7 might represent a good candidate, as it is widely
expressed in lung tissue and inflammatory cells [36].
Moreover, in vitro studies have shown that the anti-
inflammatory activity of the PDE4 inhibitor rolipram was
enhanced by a PDE7 inhibitor, although the PDE7 inhib-
itor alone was without effect [37].
Antisense oligonucleotides (AON), by their ability to
downregulate the expression of specific proteins, repre-
sent an innovative therapeutic strategy for lung diseases
[38-40]. AONs can inhibit gene expression through for-
mation of duplexes with complementary mRNA, activa-
tion of RNAseH and degradation of the duplexes or
blockade of the translation machinery [41-43]. The lung is
lined with surfactant, which is believed to facilitate AON
uptake into cells following inhalation, without the need
for specific carriers [44]. Moreover, inhaled AONs are
metabolized mostly in the lung [45], therefore limiting
systemic exposure [46]. Their clinical utility in lung dis-
eases was illustrated in a recent study where inhaled AONsRespiratory Research 2009, 10:39 http://respiratory-research.com/content/10/1/39
Page 3 of 14
(page number not for citation purposes)
were used to inhibit the allergen-induced inflammation in
asthmatic subjects [47]. We hypothesized that inhaled
AONs against selected PDE subtypes, by downregulating
the expression of their targets locally, would reduce
inflammation associated with cigarette smoke exposure.
We reasoned that a combination of AONs against PDE4
and PDE7 subtypes would mediate improved pharmaco-
logical activity as compared to PDE4 only inhibitors. This
study therefore examined the in vitro and in vivo potency
of a combination of phosphorothioate AONs directed
against PDE4B/4D and PDE7A subtypes. These AONs
incorporate 2'-deoxy-2'-Fluoro-β-D-Arabinonucleic Acid
(FANA) modifications, which have been shown to pro-
vide increased potency and increased stability as com-
pared to second generation phosphorothioate
oligonucleotides [48,49].
Methods
Antisense oligonucleotides (AON)
AONs were obtained from the University of Calgary DNA
Synthesis Laboratory (UCDNA) and were purified by
anion-exchange HPLC. AON sequences were as follows
(lowercase: DNA; bold uppercase: FANA; all with phospho-
rothioate linkages): human PDE4B/4D (5'-TCtgcccatgtctC-
CCA-3'); human PDE7A (5'-TCATgagtggcagctgcAATT-3');
mouse PDE4B/4D (5'-GGttgctcaggtctgcACAG-3'); mouse
PDE7A (5'-TCCAGatcgtgaGTGGC-3'). Control sequences
with mismatched nucleotides were as follows: for human
PDE4B/4D (5'-AGacgggtacagaGGGT-3'); human PDE7A
(5'-AGTActcaccgtcgacgTTAA-3'); mouse PDE4B/4D (5'-
GCatggtctgcagtggACTC-3'); mouse PDE7A (5'-TGCT-
CaacgtctGAGGG-3').
Cell culture and transfection
Normal human bronchial epithelial cells (NHBE) were
cultured in antibiotic-free BEGM medium (Clontech)
until 70–90% confluency was reached, and were then
transfected for 24 h with the AONs using Lipofectamine
2000 (Invitrogen). Fresh media containing TNF-α, IL-1β
and IFN-γ (10 ng/ml each; Peprotech) was added 4 h
before the end of the transfection.
Mouse models of cigarette smoke-induced lung 
inflammation. 1-week smoke model
The housing and care of mice (male C57Bl/6, Charles Riv-
ers Laboratory) used in this study were provided accord-
ing to protocols approved by Mispro Biotech's
Institutional Animal Care and Use Committee, in con-
formity with Canadian Council on Animal Care (CCAC)
guidelines. On days 1, 3, 6 and 8, groups of mice were
anesthesized with ketamine and xylazine (60 mg/kg and
12 mg/kg, i.p.) and intubated. Aerosols of vehicle (endo-
toxin-free distilled water), AONs or controls were admin-
istered into the trachea using a microsprayer (Penn-
Century). On days 6 to 9, other groups of mice were
treated by gavage with vehicle (0.5% methylcellulose) or
roflumilast (Rasayan). On days 6 to 9 (3 h after drug treat-
ment), mice were nose-only exposed to the smoke of two
2R4f reference cigarettes (University of Kentucky) per day.
Cigarette smoke was delivered to mice using a nose-only
exposure system (Proto-Werx), at a rate of 1 puff (20 ml)
per minute, as described previously [12,50]. 2-week smoke
model: On days 1, 2, 3, 4, 5, 8 and 15, groups of mice were
treated with vehicle, AONs or controls as described above.
On days 8 to 12 and 15 to 18, mice were nose-only
exposed to the smoke of two 2R4f reference cigarettes
(University of Kentucky) per day, as described above for
the 1-week smoke model. Mice were killed by anesthetic
overdose (sodium pentobarbital 88 mg/kg i.p.) and
exsanguination 20 h following the last smoke exposure.
Bronchoalveolar lavage (BAL) were performed as
described previously [50]. Differential cell counts were
determined on at least 300 cells using standard morpho-
logical criteria.
mRNA quantification
Total RNA was extracted from NHBE cells using the RNe-
asy mini kit (Qiagen); cDNA was prepared with Super-
Script™ II Reverse Transcriptase (Invitrogen) and
combined d(T)18 oligos (Biocorp) and PDE4B specific
primers (TIB MOLBIOL). Quantitative real-time PCR was
performed using the LC Fast Start SYBR Green reagent
(Roche) and gene-specific primers (TIB MOLBIOL) (see
Table 1) with the LightCycler2.0 instrument (Roche).
PDEs mRNA expression levels in BAL cells were quantified
using the Quantigene® assay (Panomics). Gene expression
was normalized to a reference gene (PPIB, GAPDH or β2
m as indicated).
Cytokines and chemokines quantification
ELISA kits for human IL-8 (BD Biosciences), human
monocyte chemoattractant protein-1 (MCP-1; R&D Sys-
tems), and murine KC (R&D Systems) were used. Mouse
pro-MMP-9 was quantified using the SearchLight array
testing service (Thermo Fisher Scientific).
Statistical analysis
Results are expressed as mean ± standard error to the
mean (SEM). Statistical comparisons between groups
were carried out using unpaired t-test.
Results
Target mRNA knock down by PDE 4B/4D and PDE 7A 
antisense oligonucleotides in human broncho-epithelial 
cells
AON sequences were designed to specifically target the
mRNA for human PDE4B/4D and synthesized with a
phosphorothioate backbone. The high sequence homol-
ogy between the catalytic domains of PDE4B and PDE4D
genes enabled the design of single AON sequences specific
for both isotypes. Phosphorothioate AON sequences were
also designed to specifically target the mRNA for humanRespiratory Research 2009, 10:39 http://respiratory-research.com/content/10/1/39
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PDE7A. Following screening for inhibition of target
mRNA expression in 293 cells and in A549 cell lines, lead
AON sequences were characterized by dose-response and
time course analysis. For the most potent AONs, chemis-
try optimisation was performed by including FANA sub-
stitutions in a gapmer configuration in order to improve
efficacy and duration of action, as well as to improve
resistance to nuclease degradation. From this screening,
two AON sequences were selected for this study, and iden-
tified as AON 4B/4D and AON 7A. Base mismatched oli-
gonucleotides were used as control sequences.
As epithelial cells lining the airways are believed to play a
critical role in the modulation of the inflammatory
response in COPD, we first assessed the effect of AON 4B/
4D and AON 7A on PDE expression levels in NHBE cells.
NHBE cells were transfected with AON 4B/4D or AON 7A
at three different doses, and PDE mRNA levels were deter-
mined 24 h later by real-time PCR analysis. Results indi-
cate that AON 4B/4D reduced PDE4B (Figure 1A) and
PDE4D (Figure 1B) mRNA in a dose-dependent manner.
At the mid (134 nM) and the high (267 nM) doses, both
PDE4B and PDE4D levels were significantly lower in cells
transfected with the 4B/4D AON as compared to cells
transfected with the control sequence. This provides evi-
dence that PDE4B and 4D mRNA inhibition is sequence-
specific and consistent with an antisense mechanism of
action. Dose-dependent and sequence-specific down-reg-
ulation of PDE7A mRNA expression was also achieved
following transfection with AON 7A (Figure 1C).
PDE4B/4D and 7A mRNA knock down by antisense 
oligonucleotides correlates with inhibition of inflammatory 
mediators production by human broncho-epithelial cells in 
vitro
We next evaluated the effect of combined 4B/4D and 7A
AONs on the functional activity of NHBE cells in vitro.
Cells were transfected with a combination of 4B/4D and
7A AONs, each at 134 or 267 nM; cells were then stimu-
lated and levels of IL-8 and MCP-1 produced were meas-
ured in cell culture supernatants by ELISA. Results indicate
that the secretion of both IL-8 (Figure 2A) and MCP-1
(Figure 2B) were dose-dependently reduced by transfec-
tion with combined 4B/4D and 7A AONs. Levels of both
chemokines were significantly lower in cells transfected
with combined AONs at 267 nM as compared to controls,
and were near baseline levels seen in non-stimulated,
non-transfected cells. The strong inhibitory activity of
combined 4B/4D and 7A AONs on IL-8 and MCP-1 secre-
tion is in line with their ability to knock down their
respective target mRNA (Figure 1).
Efficacy of locally administered PDE4B/4D and PDE7A 
AON against cigarette smoke-induced lung inflammation 
in mice, and comparison with roflumilast
We next wanted to determine whether inhibition of
PDE4B, PDE4D and PDE7A expression in the lung would
protect against lung inflammation in mice exposed to cig-
arette smoke. Mouse specific AONs were designed,
screened for target knock down in murine cell lines, and
chemically modified to include FANA substitutions. One
lead sequence specific for both mouse PDE4B and 4D
mRNAs (AON 4B/4D), and one for mouse PDE7A (AON
7A) were selected, as well as control sequences, and used
for all in vivo experiments.
Sub-acute exposure of mice to cigarette smoke leads to
lung inflammation which is comparable to the inflamma-
tory response observed in COPD patients [21,51]. We
used a nose-only sub-acute smoke model to assess the
effect of local inhibition of PDE4B, PDE4D and PDE7A
mRNA on neutrophilic inflammation. Mice were treated
by endo-tracheal delivery of combined 4B/4D and 7A
AON every other day, prior to and during cigarette smoke
exposure, which lasted for one week (Figure 3A).
Repeated smoke exposure induced a significant recruit-
ment of neutrophils in broncho-alvoalar lavage (BAL) col-
lected the day after the last smoke exposure (Figure 4A).
Table 1: Real-time PCR primer sequences
Primer Sequence 5'-3' Annealing Temperature (°C)
huPDE4B for tggcagacctgaagacaatg 59
huPDE4B rev.1 aaattcctccatgatgcgg
huPDE4B rev.2a tctttgtctccctgctgga
huPDE4D for cagaatatggtgcactgtgc 59
huPDE4D rev agtctatgaagcccacctgtg
huPDE7A for tcaggccatgcactgttact 57
huPDE7A rev cctgattctctcaataagccc
huPbib for agagcatctacggtgagcg 57
huPbib rev cttccgcaccacctcca
aReverse primer used for first strand reactionRespiratory Research 2009, 10:39 http://respiratory-research.com/content/10/1/39
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Effect of 4B/4D and 7A antisense oligonucleotides (AON) on target mRNA expression in NHBE cells Figure 1
Effect of 4B/4D and 7A antisense oligonucleotides (AON) on target mRNA expression in NHBE cells. NHBE 
cells were transfected for 24 h with AON 4B/4D, with AON 7A, or with control sequences (CTRL) at 67, 134 or 267 nM, or 
were not transfected (NT). 4 h before the end of the transfection period, fresh media containing TNF-α, IL-1β and IFN-γ was 
added. mRNA levels for (A) PDE4B, (B) PDE4D and (C) PDE7A were quantified by real-time PCR analysis and normalized to 
a reference gene (Ppib). Results are expressed as percentage of PDE mRNA levels in non-transfected cells (± SEM). *: p < 0.05; 
**: p < 0.01, ***: p < 0.001, t-test relative to CTRL (n = 3 to 9 replicates).Respiratory Research 2009, 10:39 http://respiratory-research.com/content/10/1/39
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Inhibition of inflammatory mediators by combined 4B/4D and 7A AONs in NHBE cells Figure 2
Inhibition of inflammatory mediators by combined 4B/4D and 7A AONs in NHBE cells. NHBE cells were trans-
fected for 24 h with combined 4B/4D and 7A AON or with control sequences (CTRL) at 134 or 267 nM each, or were not 
transfected (NT). 4 h before the end of the transfection period, fresh media containing TNF-α, IL-1β and IFN-γ was added. 
Non-stimulated, non-transfected cells are shown as NS-NT. IL-8 (A) and MCP-1 (B) proteins were measured in cell culture 
supernatants by ELISA. Results are expressed as percentage of chemokine levels in non-transfected cells (± SEM). **: p < 0.01; 
***: p < 0.001; t-test versus NS-NT or versus CTRL, as indicated (n = 6 replicates).Respiratory Research 2009, 10:39 http://respiratory-research.com/content/10/1/39
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Neutrophils counts in vehicle-treated and smoke exposed
animal were 5.1 × 104 ± 8.5 × 103 compared to 3.2 × 103 ±
0.9 × 103 in mice treated with vehicle but not exposed to
smoke. This was accompanied by increased secretion of
KC (54.7 ± 10.5 pg/ml in smoke-exposed versus 17.5 ± 3.0
pg/ml in non-exposed), an important neutrophil chem-
oattractant considered to be the functional homolog for
human IL-8 [52], and pro-MMP-9 (275.1 ± 91.2 pg/ml in
smoke-exposed versus 72.1 ± 28.7 pg/ml in non-
exposed), a metalloprotease produced by neutrophils and
believed to play a role in lung tissue damage [10] (Figure
4B–C). When mice were treated with combined 4B/4D
and 7A AON at 0.2 mg/kg/day, the smoke-induced neu-
trophil influx was significantly reduced when compared
to mice treated with control sequences (59% inhibition,
Figure 4A). At this dose of AONs, neutrophils, KC, and
pro-MMP-9 all returned to near baseline levels seen in
mice treated with vehicle only and not exposed to smoke
(Figure 4A–C). Treatment of mice with lower doses of 4B/
4D and 7A AON (0.008 and 0.04 mg/kg/day) was without
effect. Although macrophages were also significantly
increased in mice exposed to smoke (5.9 × 105 ± 4.6 × 104
versus 3.4 × 105 ± 2.9 × 104 in non-exposed mice), treat-
ment with PDE AONs had no effect on macrophages.
Lymphocytes were not significantly increased in this 1-
week smoke model (data not shown).
To determine whether inhibition of neutrophil recruit-
ment was correlated with PDE mRNA inhibition in vivo,
the expression of target mRNAs was measured in BAL cells
collected the day after the last smoke exposure. Results
showed that for groups in which a significant reduction of
Study protocols for cigarette smoke exposure in mice Figure 3
Study protocols for cigarette smoke exposure in mice. A) For the one-week smoke model protocol, mice were 
treated by endo-tracheal delivery of combined 4B/4D + 7A AON on days 1, 3, 6 and 8. On days 6 to 9, other groups of mice 
were treated daily with oral roflumilast. On days 6 to 9 (3 h after AON or roflumilast treatment), mice were nose-only 
exposed to the smoke of two 2R4f reference cigarettes per day. Bronchoalveolar lavages (BAL) were performed on Day 10. 
B) For the two-week smoke model protocol, mice were treated by endo-tracheal delivery of combined 4B/4D + 7A AON 
daily from Day 1 to Day 5, then once a week on Day 8 and 15. On days 8 to 12 and 15 to 18, mice were nose-only exposed to 
the smoke of two 2R4f reference cigarettes per day. BAL were performed on Day 19.
B)
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RoflumilastRespiratory Research 2009, 10:39 http://respiratory-research.com/content/10/1/39
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Efficacy of treatment with combined 4B/4D and 7A AONs against cigarette smoke-induced lung inflammation Figure 4
Efficacy of treatment with combined 4B/4D and 7A AONs against cigarette smoke-induced lung inflammation. 
Mice were treated with endo-tracheal vehicle only (VEH), with combined 4B/4D and 7A AON (0.008, 0.04 or 0.2 mg/kg/day) 
or with control sequences (CTRL, 0.2 mg/kg/day) and exposed to cigarette smoke for one week, as per protocol design 
described in Figure 3A. Neutrophil counts (A), KC (B) and pro-MMP-9 levels (C) were measured in BAL. Results are 
expressed as percentage of neutrophils, KC or pro-MMP-9 levels in vehicle-treated and smoke-exposed animals (± SEM). *: p < 
0.05; ***: p < 0.001; t-test versus vehicle-treated without smoke exposure, or versus CTRL, as indicated (compilation of 4 
independent experiments; n = 10–20 mice per group for neutrophils, 14–15 per group for KC, and 9–10 per group for pro-
MMP-9).Respiratory Research 2009, 10:39 http://respiratory-research.com/content/10/1/39
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neutrophils was obtained (treated with 0.2 mg/kg/day,
Figure 4A), there was also a significant reduction of mRNA
levels for all three PDE targets (0.2 mg/kg/day, Figure 5A–
C).
The potency of combined 4B/4D and 7A AON at reducing
cigarette smoke-induced lung inflammation was com-
pared to roflumilast. The route of administration (oral)
and dosing regimen (5 mg/kg/day) used for roflumilast
(Figure 3A) was based on a previous report showing
inhibitory activity against neutrophils in mice acutely
exposed to cigarette smoke [21]. In contrast to the effects
observed with the 4B/4D and 7A AON, roflumilast had a
small but non-significant effect on the smoke-induced
neutrophil influx (Figure 6A) and did not reduce the
secretion of KC or pro-MMP-9 (Figure 6B–C).
Sustained anti-inflammatory activity of PDE4B/4D and 
PDE7A AON following once a week treatment in cigarette 
smoke-exposed mice
The longer term efficacy of 4B/4D and 7A AON adminis-
tered to the lungs was then evaluated in a two-week smoke
exposure protocol, in which mice were treated daily with
combined AONs for one week prior to smoke exposure,
then once a week during the period of smoke exposure
(see Figure 3B). As for the one week protocol shown
above, repeated smoke exposure for two weeks resulted in
a significant recruitment of neutrophils (1.0 × 105 ± 3.2 ×
104 cells) and production of KC (78.7 ± 10.8 pg/ml) and
pro-MMP-9 (268.8 ± 38.8 pg/ml) in the airways of mice
(Figure 7A–C). In mice treated with combined 4B/4D and
7A AONs, neutrophil recruitment was significantly
blocked as compared to control mice, with doses of AONs
as low as 0.05 mg/kg/day (54% inhibition, Figure 7A).
The secretion of KC and pro-MMP-9 were reduced by
combined AON treatment in a similar fashion (Figure 7B
and 7C). These results indicate that protection against the
smoke-induced recruitment of neutrophils and release of
KC and pro-MMP-9 is still effective four days after the last
treatment with combined PDE AONs. As for the 1-week
smoke model, macrophages were significantly increased
in mice exposed to smoke for two weeks (5.5 × 105 ± 4.2
× 104), but were not affected by PDE AON treatment. On
the other hand, lymphocytes were increased following
two weeks of smoke exposure (2.7 × 104 ± 5.7 × 103 versus
5.5 × 103 ± 1.2 × 103 in non-exposed mice), and were sig-
nificantly inhibited by PDE AON treatment (66% inhibi-
tion versus CTRL at 0.1 mg/kg, p < 0.05, data not shown).
Discussion
Much interest in the field of COPD has focused on strate-
gies aimed at reducing the underlying inflammation
through broad inhibition of the PDE4 isoforms. Orally
administered second generation PDE4 inhibitors, such as
cilomilast and roflumilast, have undergone extensive
investigation and are currently in Phase III clinical devel-
opment. Although effective, dose-limiting side effects
related to the systemic exposure of these drugs have ham-
pered their clinical development. Therefore, there is still a
need for more selective and/or more potent PDE inhibi-
tors with improved therapeutic ratios.
Increased interest in the therapeutic use of AONs has been
fueled by recent pre-clinical [38,44,53-55] and clinical
studies [47] showing their potential benefit in respiratory
disorders involving inflammation such as asthma. We
have developed FANA-modified antisenses oligonucle-
otides specifically targeting PDE isotypes 4B, 4D and 7A,
as a potential new inhaled drug for the treatment of
COPD. In NHBE cells, high levels of PDE4B, 4D and 7A
mRNA inhibition were correlated with reduced functional
activity, as illustrated by dose-dependent inhibition of IL-
8 and MCP-1 secretion. The potency of combined PDE4B/
4D and 7A AON on inflammatory markers in vitro is in
line with their protective effect in vivo, as evidenced by
their ability to reduce the smoke-induced recruitment of
neutrophils and secretion of KC and MMP-9 in mice. Inhi-
bition of neutrophil recruitment was also associated with
PDE mRNA inhibition in vivo. Interestingly, we observed
that the dose required to achieve significant inhibition of
the three PDE targets at the mRNA level (0.2 mg/kg/day)
was the same as the dose required to block the recruitment
of neutrophils, KC and pro-MMP-9. At lower doses where
only PDE4B mRNA inhibition was measured, no reduc-
tion in neutrophil recruitment was observed (see Figures
4A and 5A). Because PDE4B, 4D and 7A are expressed to
different levels in different cell types, these data do not
allow us to determine in which cellular subset in the BAL
fluid the inhibition of PDE mRNA was the most efficient.
The fact that total RNA from the mixed cell populations
present in the BAL was measured might reflect this limita-
tion. Nevertheless, these results are consistent with the
idea that downregulating different PDE subtypes in differ-
ent cell populations which together orchestrate the
inflammatory response is required to achieve a protective
effect against neutrophils in vivo. Moreover, and as previ-
ously shown in PDE4B and PDE4D knock out mice [20],
these data support the idea that different PDE isotypes
play complementary roles in the control of inflammatory
cell recruitment. In the acute smoke exposure protocol
used here (1-week model), orally delivered roflumilast at
5 mg/kg/day partially reduced neutrophil recruitment
(20% reduction), but statistical significance could not be
reached, and had no effect on KC or pro-MMP-9 secretion
(Figure 6). Martorana et al. reported that oral roflumilast
at 5 mg/kg inhibited neutrophils by 30% following one
acute (20 minutes) exposure to cigarette smoke [21]. The
longer smoke exposure period used here might explain
the difference between the studies. Yet, the greater efficacy
of the combined AONs PDE4B/4D and PDE7A supportsRespiratory Research 2009, 10:39 http://respiratory-research.com/content/10/1/39
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Target mRNA expression in BAL cells following treatment with 4B/4D and 7A AON and smoke exposure Figure 5
Target mRNA expression in BAL cells following treatment with 4B/4D and 7A AON and smoke exposure. Mice 
were treated with combined 4B/4D and 7A AON (0.008, 0.04 or 0.2 mg/kg/day) or with control sequences (CTRL, 0.2 mg/kg/
day) and exposed to cigarette smoke for one week, as per protocol design described in Figure 3A. PDE4B (A), PDE4D (B) 
and PDE7A (C) mRNA expression were quantified in BAL cells lysates using the Quantigene® assay, and normalized to the 
expression of GAPDH used as a reference gene. Results are expressed as percentage of PDE mRNA levels in vehicle-treated 
and smoke-exposed animals (± SEM). *: p < 0.05; **: p < 0.01; ***: p < 0.001; t-test versus CTRL (compilation of 4 independent 
experiments, n = 10 to 20 mice per group).Respiratory Research 2009, 10:39 http://respiratory-research.com/content/10/1/39
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the hypothesis that the anti-inflammatory activity of
PDE4 inhibitors might benefit from the addition of a
PDE7 inhibitor.
Besides neutrophils, lung macrophages are believed to play
an important role in COPD, in part by their ability to
release TNF-α, which can drive neutrophil influx and acti-
vate MMP-12 release, leading to extracellular matrix degra-
dation [50]. In both the 1-week and the 2-week smoke
models used here, macrophages were significantly
increased in lung lavages upon smoke exposure. However,
no reduction in macrophage counts were observed in mice
treated with PDE4B/4D and 7A AONs, nor with roflumilast
(data not shown). Although roflumilast has been shown to
reduce macrophage density in lung tissue of mice chroni-
cally exposed to smoke (7 months), no effect of roflumilast
on macrophages was seen following acute smoke exposure
in that study [21], which is in line with our results. Thus,
lack of efficacy on macrophages in the acute smoke expo-
sure protocols used here may reflect the limitations of the
acute model, and therefore may not be predictive of the
outcome in chronic smoke exposure regimens.
When tested in a two-week smoke exposure protocol,
combined PDE4B/4D and 7A AONs (at 0.05 mg/kg/day)
were found to significantly reduce neutrophil influx, as
well as KC and pro-MMP-9 in lung lavages collected four
days after the last AONs treatment (Figure 7). In addition,
treatment with combined PDE4B/4D and 7A AONs also
resulted in significant inhibition of lymphocyte recruit-
ment (data not shown). Results from these experiments
suggest that once a steady state level of AONs is reached in
the lung, a once-a-week treatment regimen could be suffi-
cient to keep cellular inflammation to low levels.
Although the results from this 2-week smoke exposure
protocol are encouraging, more studies are needed to ver-
ify whether protection against inflammation is main-
tained in more chronic smoke exposure models, and
whether PDE AON treatment can be beneficial on long
term endpoints such as emphysema.
Delivery of AON directly to the lung via inhalation
presents key advantages over systemic delivery of small
molecule PDE4 inhibitors. Inhalation of AONs achieves
appreciable local lung concentrations at the site of action,
at lower administered doses. In a 14-day inhalation study
in monkeys, PDE-targeting FANA AONs were found to be
safe and well tolerated at all dose levels tested (from 0.05
to 2.5 mg/kg/day) [46]. Moreover, pharmacokinetic stud-
ies indicated very low levels of AON in plasma (<1%), and
no plasma accumulation was obtained after repeated
doses. In humans, there were no detectable levels of AON
in plasma following inhalation for four consecutive days
of 1.5 mg of TPI ASM8, an AON drug candidate in devel-
opment for the treatment of asthma [47].
Effect of treatment with roflumilast on cigarette smoke- induced lung inflammation Figure 6
Effect of treatment with roflumilast on cigarette 
smoke-induced lung inflammation. Mice were treated 
with oral vehicle only or with oral roflumilast (5 mg/kg/day) 
and exposed to cigarette smoke for one week, as per proto-
col design described in Figure 3A. Neutrophil counts (A), 
KC (B) and pro-MMP-9 levels (C) were measured in BAL. 
Results are expressed as percentage of neutrophils, KC or 
pro-MMP-9 levels in vehicle-treated and smoke-exposed ani-
mals (± SEM). ***: p < 0.001; t-test versus vehicle-treated 
without smoke exposure (compilation of 4 independent 
experiments, n = 12–21 mice per group for neutrophils and 
KC, and 3–6 per group for pro-MMP-9).Respiratory Research 2009, 10:39 http://respiratory-research.com/content/10/1/39
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Sustained effect of 4B/4D and 7A AONs following once a week treatment and two weeks of smoke exposure Figure 7
Sustained effect of 4B/4D and 7A AONs following once a week treatment and two weeks of smoke exposure. 
Mice were treated with endo-tracheal vehicle only (VEH), with combined 4B/4D and 7A AON (0.05, 0.1 or 0.2 mg/kg/day) or 
with control sequences (CTRL, 0.2 mg/kg/day) daily for one week, then once a week during the 2-week smoke exposure 
period, as per protocol design described in Figure 3B. Neutrophil counts (A), KC (B) and pro-MMP-9 levels (C) were meas-
ured in BAL. Results are expressed as percentage of neutrophils, KC or pro-MMP-9 levels in vehicle-treated and smoke-
exposed animals (± SEM). *: p < 0.05; **: p < 0.01; ***: p < 0.001; t-test versus vehicle-treated without smoke exposure, versus 
vehicle-treated or versus CTRL, as indicated (n = 4 to 8 mice per group).Respiratory Research 2009, 10:39 http://respiratory-research.com/content/10/1/39
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Conclusion
Findings from the present study show for the first time
that a multi-target AON-based approach directed against
specific PDE isoforms is effective at reducing key inflam-
matory markers characterizing COPD. While others have
begun to explore the concept that combined or dual
PDE4/PDE7 inhibitors may provide a better therapeutic
ratio [35], our data support this idea and suggest that such
an approach is valuable for potent inhibition of key
inflammatory markers. Together, the potential favorable
safety profile of locally delivered AON, combined with
the improved efficacy resulting from direct access to target
cells in the lung, support further development of PDE
AON for chronic respiratory indications such as COPD
and asthma.
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